United Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10. Earnings rose 42% year over year on the back of higher product sales. See the ...

Shares of United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the firm, MarketBeat reports.

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Molecular Partners (MOLN – Research Report), ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

United Therapeutics is down 11.5% since the beginning of the year, and at $318.89 per share, it is trading 22.2% below its 52-week high of $410 from November 2024.

HC Wainwright reissued their buy rating on shares of United Therapeutics (NASDAQ:UTHR – Free Report) in a report published on Thursday morning,Benzinga reports. HC Wainwright currently has a $425.00 ...

United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by ...

United Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10. Earnings rose 42% year over year on the back of higher product sales.